MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
2.410
-0.020
-0.82%
Pre Market: 2.390 -0.02 -0.83% 08:38 09/10 EDT
OPEN
2.430
PREV CLOSE
2.430
HIGH
2.450
LOW
2.380
VOLUME
248
TURNOVER
0
52 WEEK HIGH
2.610
52 WEEK LOW
1.330
MARKET CAP
336.28M
P/E (TTM)
-5.4426
1D
5D
1M
3M
1Y
5Y
1D
Inhibikase advances IKT-001 in pivotal PAH Phase 3
TipRanks · 1d ago
Weekly Report: what happened at IKT last week (0831-0904)?
Weekly Report · 3d ago
Monthly top ideas from Oppenheimer include MA, MRVL, CMG, and more
Seeking Alpha · 09/02 16:25
Weekly Report: what happened at IKT last week (0824-0828)?
Weekly Report · 08/31 09:10
Weekly Report: what happened at IKT last week (0817-0821)?
Weekly Report · 08/24 09:11
Weekly Report: what happened at IKT last week (0810-0814)?
Weekly Report · 08/17 09:11
Analysts Are Bullish on Top Healthcare Stocks: Evotec AG (EVO), Taysha Gene Therapies (TSHA)
TipRanks · 08/14 15:30
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth
TipRanks · 08/13 06:01
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.